ClinicalTrials.gg
CompletedNCT02477306Updated Jun 22, 2015

A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)

A Phase 1 interventional study of Idiazole 20mg DR tabs and PARIET 20 mg DR tabs in Healthy, sponsored by Genuine Research Center, Egypt. Completed at 1 site in Egypt. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by Genuine Research Center, Egypt · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Rabeprazole from Idiazole 20mg DR tabs (GSK, Egypt)and PARIET 20 mg DR tabs (JANSSEN, EGYPT) after a single oral dose administration of each to healthy adults under fasting conditions.

Read the detailed description

Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e. The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%.

A comprehensive final report will be issued upon the completion of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Genuine Research Center, Egypt is the lead sponsor of 38 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female, age 18 to 55 years, inclusive.
  2. Body weight within 15% of normal range according to the accepted normal values for (BMI).
  3. Medical demographics without evidence of deviation from normal medical condition.
  4. Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
  5. Subject does not have allergy to the drugs under investigation.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known allergy to the products tested.
  2. Subjects whose values of were outside the accepted normal ranges.
  3. Female subjects who are pregnant, nursing or taking pills.
  4. Medical demographics with evidence of deviation from normal medical condition.
  5. Results of laboratory tests which are clinically significant.
  6. Acute infection within one week preceding first study drug administration.
  7. History of drug or alcohol abuse.
  8. Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
  9. Subject is on a special diet (for example subject is vegetarian).
  10. Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
  11. Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
  12. Subject has a history of severe diseases which have direct impact on the study.
  13. Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.
  14. Subject intends to be hospitalized within 6 weeks after first study drug administration.
  15. Subjects who, through completion of this study, would have donated more than 500 ml of blood in 7 days, or 750 ml of blood in 30 days, 1000 ml in 90 days, 1250 ml in 120 days, 1500 ml in 180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Study group

    60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods

    Drug: Idiazole 20mg DR tabs · Drug: PARIET 20 mg DR tabs

Interventions

06

What researchers measure

Primary outcomes

  1. Maximal measured plasma concentration (Cmax)

    Serial blood samples for determination of study drug will be collected pre-dose and at 0.00, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.33, 4.67, 5.0, 5.33, 5.67, 6.00, 8.00, 12.0 and 14.0 hours post dose, relative to dosing on Day 1 in each cross over period.

    Time frame: Up to 14 hours post dose in each treatment period

  2. Area under the plasma concentration-time curve from time zero to the last measurable concentration (t) (AUC [0 to t])

    (AUC \[0 to t\]) will be calculated by the linear trapezoidal method.

    Time frame: Up to 14 hours post dose in each treatment period

  3. Area Under the plasma concentration-time curve from time zero to infinity (AUC [0 to infinity])

    AUC (0 to infinity) will be calculated as the sum of the AUC (0 to t) plus the ratio of the last measurable plasma concentration to the elimination rate constant

    Time frame: Up to 14 hours post dose in each treatment period

Secondary outcomes

  1. Time of the maximum plasma concentration (tmax)

    If the Tmax occurs at more than time point, then tmax will be considered for the first occurrence.

    Time frame: Up to 14 hours post dose in each treatment period

  2. Apparent first-order elimination or terminal rate constant (K¬e)

    K¬e will be calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations

    Time frame: Up to 14 hours post dose in each treatment period

  3. Terminal half life (t1/2e)

    The elimination or terminal half-life will be calculated as 0.693/ Ke

    Time frame: Up to 14 hours post dose in each treatment period

07

Study locations

1 site
  • Genuine Research Center GRC
    Cairo, Egypt
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2015
First posted
Jun 22, 2015
Start
Mar 2014
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02477306
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 22, 2015
Start date
Mar 2014
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Jun 22, 2015

Study contacts

Ahmed Elshafeey, Ph.D. Pharma
study director · Genuine Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion